Compare SY & PLYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SY | PLYX |
|---|---|---|
| Founded | 2013 | 2014 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 258.6M | 271.8M |
| IPO Year | 2018 | N/A |
| Metric | SY | PLYX |
|---|---|---|
| Price | $2.87 | $5.78 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $5.50 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 552.7K | 378.0K |
| Earning Date | 05-15-2026 | 05-22-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $59.90 | N/A |
| Revenue Next Year | $37.93 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.75 | $2.20 |
| 52 Week High | $6.28 | $9.18 |
| Indicator | SY | PLYX |
|---|---|---|
| Relative Strength Index (RSI) | 51.06 | 47.43 |
| Support Level | $2.80 | $4.95 |
| Resistance Level | $2.92 | $7.32 |
| Average True Range (ATR) | 0.15 | 0.88 |
| MACD | 0.02 | -0.12 |
| Stochastic Oscillator | 89.74 | 22.82 |
So-Young International Inc is an online destination for discovering, evaluating, and reserving medical aesthetic services in China. Its business model comprises four integrated components: professional content and its distribution through social media networks and its targeted media platforms in China, a social community characterized by signature user-generated content, Online reservation services for a medical aesthetic treatment, and the research, development, production, sales and agency of laser and other optoelectronic medical beauty equipment. It generates revenue from information services fees and reservation services fees from medical aesthetic service providers.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.